A Multi-centre Survey on Tramadol Abuse in Singapore
1 other identifier
observational
1,000
1 country
3
Brief Summary
The rampant prescription of opioid has in part contributed to the ongoing worldwide opioid crisis. In the United States of America, it is estimated that death from the use of opioids outnumber death from motor vehicle accident deaths by more than 40%. Consequently, many countries such as America and Canada have drawn up guidelines pertaining to safe opioid prescribing. Tramadol is often used by pain physicians to treat chronic pain. As it is a weak opioid and unscheduled in many countries, it is often considered to have a lower addiction potential compared to strong opioids. Despite this, the literature does reveal evidence of abuse, addiction and withdrawal - although the incidence of this is unclear. In this study, the investigators aim to determine the prevalence of tramadol misuse in a pain clinic population. The investigators also aim to determine the real-life compliance of physicians to guidelines provided by International regulatory bodies (CDC) and the modifiable risk factors associated with tramadol misuse.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2020
Shorter than P25 for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2020
CompletedFirst Submitted
Initial submission to the registry
March 10, 2021
CompletedFirst Posted
Study publicly available on registry
March 24, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2021
CompletedMarch 24, 2021
March 1, 2021
8 months
March 10, 2021
March 21, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Current Opioid Misuse Measure (COMM)
The primary outcome is the prevalence of Current Opioid Misuse (defined as a COMM score of 9 or greater) in the patients included in the cross-sectional study (ie patients who are on tramadol)
Baseline
Secondary Outcomes (3)
Patient Health Questionnaire-9 (PHQ-9)
Baseline
General Anxiety Disorder-7 (GAD-7)
Baseline
Opioid Risk Tool (ORT)
Baseline
Eligibility Criteria
Patients who attends pain clinic in SGH, SKGH and CGH.
You may qualify if:
- All patients attending pain clinic in Singapore General Hospital, Seng Kang General Hospital and Changi General Hospital
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
Changi General Hospital
Singapore, Singapore
Seng Kang General Hospital
Singapore, Singapore
Singapore General Hospital
Singapore, Singapore
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 10, 2021
First Posted
March 24, 2021
Study Start
December 1, 2020
Primary Completion
July 31, 2021
Study Completion
August 1, 2021
Last Updated
March 24, 2021
Record last verified: 2021-03